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 Classical Clinical Diagnosis of Parkinson’s Disease 
 Parkinson’s disease (PD) is considered to be the second 
most common neurodegenerative disease with an onset 
in the 5th or 6th decade. It is estimated to affect about 
1–2% of individuals in this age group  [1] . According to the 
UK PD Brain Bank criteria, the diagnosis of PD is based 
on three steps. First, the diagnosis of PD can be made if 
bradykinesia is associated with another main symptom, 
i.e. rigidity, tremor or postural instability  [2] . Second, one 
has to check the exclusion criteria. Typical examples are 
a history of repeated strokes with stepwise progression of 
parkinsonian features, multiple head injuries, encephali-
tis, oculogyric crisis, neuroleptic treatment, toxins like 
manganese, carbon monoxide or MPTP, cerebral tumor, 
communicating hydrocephalus on CT scans, strictly uni-
lateral features after 3 years, sustained remission, more 
than one relative affected with PD, and typical features of 
atypical PD such as cerebellar, pyramidal or oculomotor 
symptoms. The third step involves the ascertainment of 
supportive criteria for PD. Among these, unilateral onset 
and persistent asymmetry, excellent response to levodo-
pa, severe levodopa-induced dyskinesia, and disease pro-
gression support a diagnosis of PD. These criteria are 
used worldwide both for clinical diagnosis in private 
practice and hospitals and also for clinical trials. Despite 
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 The diagnosis of Parkinson’s disease (PD) follows the UK 
Brain Bank Criteria, which demands bradykinesia and one 
additional symptom, i.e. rigidity, resting tremor or postural 
instability. The latter is not a useful sign for the early diagno-
sis of PD, because it does not appear before Hoehn and Yahr 
stage 3. Early symptoms of PD which precede the onset of 
motor symptoms are hyposmia, REM sleep behavioral disor-
der, constipation, and depression. In addition, an increasing 
number of patients whose PD is related to a genetic defect 
are being described. Thus, genetic testing may eventually 
develop into a tool to identify at-risk patients. The clinical 
diagnosis of PD can be supported by levodopa or apomor-
phine tests. Imaging studies such as cranial CT or MRI are 
helpful to distinguish idiopathic PD from atypical or second-
ary PD. SPECT and PET methods are valuable to distinguish 
PD tremor from essential tremor if this is clinically not pos-
sible. Using all of these methods, we may soon be able to 
make a premotor diagnosis of PD, which will raise the ques-
tion whether early treatment is possible and ethically and 
clinically advisable.  Copyright © 2010 S. Karger AG, Basel 
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the existence of these carefully established criteria, the 
authors themselves  [2] emphasize that the correlation be-
tween clinical signs and neuropathology with Lewy bod-
ies is not very strong. If clinical examination is the only 
diagnostic tool applied, Lewy bodies are only found in 
76% of patients who were diagnosed with PD  [3] . It should 
be noted, however, that the UK PD Brain Bank Criteria 
were developed in a restrictive context for research pur-
poses.
 Despite the widespread use of these criteria, there are 
also certain drawbacks. Postural instability, for example, 
is not a very useful clinical symptom at the onset of the 
disease when the diagnosis still has to be established. This 
symptom does not manifest before the patient has reached 
Hoehn and Yahr (HY) stage 3, which is an advanced stage 
 [4] . Therefore, postural instability is not a good tool for 
early diagnosis. Modern treatment may even postpone 
the onset of HY stage 3, and therefore other symptoms 
may turn out to be more helpful for diagnosis.
 The initial clinical diagnosis of PD is based on the 
presence of resting tremor, micrographia, hypomimia, 
impaired arm swing, muscle pain, and slowed repetitive 
movements.
 Tremor 
 In most cases, resting tremor starts in the upper ex-
tremities and is unilateral (HY stage 1). Thereafter, it 
spreads to the other upper limb or to the ipsilateral lower 
limb. There are, however, also patients with initial tremor 
in the lower limbs, and it is quite possible that we often 
miss this site because of the larger weight of the legs. At 
the beginning, tremor only occurs intermittently  [5] , 
which explains why some patients notice their tremor 
first at times of stress. There are reports that over the 
years tremor may even decline when the patients enter 
the late stages of PD  [6] . Typically, PD is associated with 
resting tremor, but action tremor is also found in many 
patients  [7] . A good clinical test to unmask existing rest-
ing tremor is serial subtraction (e.g. of 7 from 100) with 
the eyes closed. The relationship between essential trem-
or (ET) with action tremor and PD with resting tremor is 
not a simple one because there are many patients with 
‘mixed’ tremor who may develop an apparently more be-
nign type of PD  [8] . PET studies indicate that tremor is 
not as closely related to the decrease in dopamine produc-
tion as are bradykinesia and rigidity  [9] , which is also sug-
gested by the decline in tremor in late stages. One should 
be cautious, however, of the fact that some patients with 
ET may later also develop resting tremor  [10] , which does 
not mean that they have developed PD.
 Bradykinesia 
 The term akinesia should be avoided, because most 
patients are not really akinetic, at least not in the first 
years of their PD career. Thus, bradykinesia may be the 
better alternative. Some authors, however, use the term 
akinesia to describe the inability to initiate movements 
and not as a description of total immobility. Marsden  [11] 
defined bradykinesia as slowness of speed, which de-
scribes the most common clinical symptom in PD best. 
Therefore, the UK PD Brain Bank Criteria define brady-
kinesia as the most important feature for the diagnosis of 
PD  [2] . Clinical expressions of bradykinesia are hypo-
mimia, which is commonly more prominent on one side 
of the face, reduced arm swing on one side, which is often 
misinterpreted by patients and physicians as an orthope-
dic problem, or problems with writing and cutting food, 
to name just a few. In particular, repetitive movements 
are impaired, and in my own practice I consider reduced 
arm swing and impaired repetitive movements of the 
hands (pronation/supination) as one of the most useful 
features both for the diagnosis of PD and for the assess-
ment of the effects of treatment. Handwriting should al-
ways be tested by asking the patient to write a given sen-
tence five times, because the amplitude declines with the 
number of repeats. As mentioned above, the severity of 
bradykinesia correlates very well with the dopaminergic 
deficit  [9, 12] .
 Rigidity 
 Testing for rigidity should be done with irregular 
movements to avoid counteraction or facilitation by the 
patient. Rigidity is noticed as a permanently increased 
muscle tone independent of stretching the agonist or an-
tagonist muscle. Cogwheel rigidity is normally encoun-
tered in more advanced stages, but is very characteristic 
of PD. In particular, asymmetric rigidity is a strong indi-
cator of PD. In case of uncertainty about the presence of 
rigidity, the Froment maneuver should be applied; this 
consists in voluntary movement of one limb whilst the 
investigator checks for a resulting increase in muscle tone 
in the opposite limb  [13] . Confusion and uncertainty de-
velops when patients with ET also present with a cog-
wheeling phenomenon, which is caused by intermittent 
increases of tremor when the examiner performs repeti-
tive passive movements.
 Postural Instability 
 As mentioned above, postural instability is not a very 
useful cardinal symptom in the early stages of PD, be-
cause, by definition, this symptom does not occur before 
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HY stage 3. With the pull test, the examiner should in-
form the patient to resist a sudden pull or make a correct-
ing step if necessary. Taking more than one and espe-
cially more than four steps to prevent falling is considered 
as impaired postural control  [14] . Postural instability 
presents on average 5 years after the onset of PD  [15] . 
Early presentation with postural instability and gait dis-
orders may be indicative of progressive supranuclear pal-
sy  [16, 17] . It is important to remember that up to 70% of 
the elderly have impaired postural reflexes, which is an-
other reason why in our view this so-called cardinal 
symptom is misleading  [14] . On the contrary, it may be 
the cause for many false-positive diagnoses.
 Premotor Signs in PD 
 The most recent studies have indicated that several 
non-motor symptoms are associated with an increased 
risk for the later development of PD. More than 90% of all 
PD patients present with non-motor symptoms during 
the course of their disease  [18] . According to Braak et al. 
 [19] , PD affects not only the dopaminergic neurons, but 
also glutamatergic, cholinergic, serotonergic and adren-
ergic neurons in the brain and in the autonomic nervous 
system  [20] . In the late 1980s, Wakabayashi et al.  [21] al-
ready described abnormalities of the autonomic nervous 
system, which was corroborated by more recent studies 
by Braak et al.  [22] .  Table 1 gives a short summary of the 
most frequent non-motor features in PD. James Parkin-
son claimed in his  Essay on the Shaking Palsy that the 
disease does not affect the senses and intellect; unfortu-
nately this is not correct. It is our belief that because hy-
posmia is present in more than 90% of all PD patients, it 
should be regarded as a new cardinal symptom  [23] . One 
has to consider, however, that only about 60% of our pa-
tients actually noticed their hyposmia or anosmia  [24] . 
Sniffing sticks are a useful olfactory test ( fig. 1 ).
 There is no difference between patients with the trem-
or-dominant, rigid-akinetic or equivalence type; all of 
them present with hyposmia  [24] . Thus, hyposmia is a 
common phenomenon which is present before motor 
symptoms occur  [25] . Specificity is not 100%, but this 
also applies to tremor, rigidity and bradykinesia. Even 
resting tremor can be a monosymptomatic feature and 
may never convert to PD. It may be helpful, however, for 
the categorization of a parkinsonian syndrome to take 
into consideration that whilst olfactory testing is gener-
ally abnormal in idiopathic PD, it is normal in PD due to 
parkin defects  [26] , in vascular PD  [27] and in toxin-in-
duced PD such as MPTP-induced PD  [28] . We and others 
have shown that olfactory tests may be a useful tool to 
identify PD in the so-called premotor phase  [29–32] . Our 
own group has shown that patients who lose their sense 
of smell in their mid-50s have an increased risk for the 
later development of PD. We found that amongst 30 pa-
tients with hyposmia or anosmia one patient presented 
with typical PD; with the additional use of transcranial 
parenchymal sonography, 11 patients were found to have 
hyperechogenicity of the midbrain, which was shown by 
Becker et al.  [33] to be a classical sign of PD. Of these 11 
patients with hyperechogenicity, 6 showed a reduced do-
pamine transporter activity on functional PET scanning 
 [30] . Some years later, 2 of those patients had also devel-
oped motor features of PD  [31] . Ponsen et al.  [29] per-
formed studies in an even larger cohort, and found that 
about 10% of patients who presented with hyposmia de-
veloped typical PD several years later. In conclusion, hy-
posmia is certainly a cardinal symptom of PD, similar to 
the more classical ones described by Hughes et al.  [2] . Un-
Table 1. Non-motor features in PD
Autonomic dysfunction
Orthostatic hypotension
Urinary incontinence
Impotence
Constipation
Sialorrhea
Anhidrosis
Sensory problems
Olfactory dysfunction
Impaired color discrimination
Pain
Sleep disorders
RBD
Restless legs
Insomnia
Sudden onset of sleep
Daytime somnolence
Sleep fragmentation
Neuropsychiatric symptoms
Anhedonia
Apathy
(Fatigue)
Depression
Psychosis
Dementia
Anxiety
Panic attacks
Miscellaneous
Seborrhea
Blurred vision
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fortunately, hyposmia is not a good marker for cell degen-
eration because it changes in an unpredictable manner 
during the course of the disease  [34] .
 Other early signs of PD are depression, constipation 
and REM sleep behavioral disorder (RBD). Iranzo et al. 
 [35] assessed retrospectively 44 consecutive patients with 
a history of RBD of at least 2 years. They showed that 45% 
of patients with RBD have developed a neurological dis-
order at a mean follow-up of 5.1 years with emerging di-
agnoses of PD in 9 patients, dementia with Lewy bodies 
in 6 patients, cerebellar type multiple system atrophy in 1 
patient and mild cognitive impairment in 4 patients. 
Thus, close follow-up of patients with idiopathic RBD 
may facilitate early diagnosis of neurodegenerative dis-
eases. Stiasny-Kolster et al.  [36] combined RBD with ol-
factory dysfunction as a possible indicator for PD and oth-
er   -synucleinopathies. They could show that RBD pa-
tients have a profound impairment of olfaction and that 
may reflect stage 2 according to the Braak criteria for PD 
 [19] . Besides urogenital, cardiovascular and thermoregu-
latory problems  [37] , patients suffer from gastrointestinal 
problems such as constipation. According to Braak’s hy-
pothesis, the first Lewy bodies occur in the Meissner and 
Auerbach plexuses, which would explain the loss or de-
crease in gut motility  [22] which is the cause of the unpre-
dictable absorption of anti-Parkinson medication. Con-
stipation occurs in many patients with PD before the on-
set of motor symptoms  [38] ; the same is also true for RBD 
 [39, 40] . Finally, depression precedes motor symptoms in 
30% of patients with PD  [41, 42] . Reijnders et al.  [43] have 
described major depression, minor depression and dys-
thymia in 17, 22 and 13% of PD patients, respectively. In a 
survey of German PD patients, we found that only about 
a third of all PD patients did not present with psychiatric 
problems (depression, psychosis or dementia) when they 
were screened using rating scales  [44] . This indicates that 
all patients with depression should undergo a careful neu-
rological examination to check for PD symptoms. All of 
these symptoms are non-motor and not very sensitive and 
specific, and therefore an inexpensive screening test for 
PD would be desirable. Most recent reports  [45] claim that 
melanine is elevated in peripheral blood in patients with 
PD and is an indicator of dopaminergic neuron break-
down. In this study, the authors compared PD patients 
with controls; 5 of the controls showed elevated melanine 
antibody binding and 3 of the 5 also had hyposmia. The 
authors report that after several years, 3 of the abnormal 
5 ‘controls’ had subtle signs of PD. Nonetheless, these pre-
liminary reports have to be confirmed in more extensive 
studies before one can speculate on their value.
 Bedside Tests 
 It is a common experience that levodopa and apomor-
phine tests are quite useful in establishing a diagnosis of 
PD. Most centers give 200 mg levodopa/carbidopa in liq-
uid form to the patient and expect to see an improvement 
 Fig. 1. Sniffin’ Stick set. 
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in the Unified Parkinson Disease Rating Scale (UPDRS) 
of 30% or more. This definition, however, may be too re-
strictive in patients with a very mild form of PD. The apo-
morphine test is performed with 50   g/kg body weight 
and should also result in an improvement in the UPDRS 
by 30% or more. It has to be stated, however, that the apo-
morphine challenge test remains controversial with low 
predictive values particularly in the Parkinson variant of 
multiple system atrophy and also progressive supranucle-
ar palsy. Tremor does not necessarily have to improve in 
these tests, which once more underlines that parkinso-
nian resting tremor may not be due only to the dopami-
nergic deficit. Müller et al.  [46] claim that the apomor-
phine test is less reliable than the levodopa test. Unfortu-
nately, there are PD patients who show no response in 
either test. It is still unclear as to whether a levodopa test 
in young onset patients leads to priming. This putative 
priming phenomenon was seen in young onset patients 
who developed dyskinesias after a levodopa test had been 
performed years before, when they received, having been 
treated with dopamine agonists or other substances for 
months or years, again levodopa  [47] .
 Laboratory Tests 
 Basic tests should include thyroid and liver function 
tests, and measurement of electrolytes and coeruloplas-
mine  [48] . Copper and coeruloplasmine are relevant in 
PD cases with onset prior to 50 years.
 The most recent studies  [49] indicate that we may be 
at the advent of a lab test for PD. This has been suggested 
by a recent work on activated microglia in the basal gan-
glia  [50] . It is of particular interest that the binding of 
anti-melanine antibodies was particularly high in pa-
tients in the early stages of the disease when presumably 
the majority of dopamine neurons die. As mentioned ear-
lier, in the so-called control group some patients with el-
evated antibody titers and hyposmia later developed PD. 
Thus, there is hope that such a test may be a new and fas-
cinating tool for the diagnosis of PD.
 Imaging 
 CT or MRI scans are not useful in the diagnosis of id-
iopathic PD but rather to discriminate between atypical 
and symptomatic PD.
 Dopamine transporter scans, dopamine receptor 
scans, meta-iodobenzyl-guanosine scans and glucose 
scans are helpful to reach a diagnosis in difficult cases 
where it is clinically impossible to differentiate between 
ET and PD or between idiopathic or atypical PD. The cur-
rently available diagnostic techniques such as dopamine 
transporter SPECT  [51] , F-Dopa PET  [52] or even MIBG 
scintigraphy  [53] certainly have a high sensitivity. The 
first two methods analyze dopamine function in the pre-
synaptic neuron, and the MIBG scintigraphy demon-
strates impairment of the postganglionic part of the sym-
pathetic nervous system. The latter is abnormal in PD, 
but normal in atypical PD and in healthy persons. Pa-
tients with atypical PD have an impairment of the pre-
ganglionic part of the sympathetic nervous system. These 
nuclear medicine methods are useful not only for very 
early detection of PD but also for the differential diagno-
sis of mono-symptomatic tremor in PD versus ET. Most 
recently, Tang et al.  [54] have shown that the use of fluo-
rodeoxyglucose PET and an automated image-based 
classification procedure results in a high specificity in 
distinguishing between parkinsonian disorders.
 Genetic Tests 
 In the future, we may have to consider PD as a genetic 
disease, although I doubt this. More than ten gene defects 
are known to be associated with a parkinsonian syn-
drome  [55] , which show similarities to the idiopathic Par-
kinson syndrome. It is extremely difficult to identify 
which patients should be tested, particularly because of 
the enormous costs of these analyses. In families with the 
LRRK2 deficiency  [56] , which has an autosomal-domi-
nant trait, the problem will occur that some individuals 
will learn that they are positive for the causative point 
mutation decades before they may develop a PD syn-
drome. This problem resembles very much the problem 
of predictive genetic testing for Huntington’s disease, and 
we will have to establish rules as to how to deal with such 
patients.
 Maybe in the near future patients who have a relative 
with PD or who are younger than 45 could have a genet-
ic microchip analysis performed.
 Additional Diagnostic Tests 
 Many groups consider parenchymal sonography  [35] 
as a supportive diagnostic tool because it shows mesence-
phalic hyperechogenicity contralateral to the clinically 
predominantly affected side. Unfortunately, the meth-
 Diagnosis of Parkinson’s Disease Neurodegenerative Dis 2010;7:284–290 289
od’s sensitivity and specificity are far from 100%  [57] , and 
frequently temporal bone thickness does not permit reli-
able testing. Quantitative tremor analysis may be used to 
assess tremor amplitudes and to unmask any tremor by 
using hand weights.
 Early Treatment in PD 
 Recent recommendations suggest the initiation of PD 
treatment immediately after establishing the diagnosis. 
This view is supported by studies with rasagiline using a 
delayed start design  [58, 59] . It was shown in both studies 
that the early start of treatment is beneficial for the pa-
tients, probably due to disease modification by the MAO-
B inhibitor rasagiline. Lately, some retrospective analyses 
derived from trials with entacapone and rotigotine 
showed the same trend. A prospective study with the do-
pamine agonist pramipexole (PROUD study) has been 
published in poster form and was not positive, i.e. there 
was no difference in motor function and dopamine trans-
porter imaging between patients with immediate and 
those with delayed initiation of therapy with pramipex-
ole. These studies seem to indicate that patients should 
start treatment early. Furthermore, a study on quality of 
life issues  [60] is rather interesting because it shows that 
patients who delayed therapy had a lower quality of life 
than those who started various treatments immediately. 
These studies allow the establishment of modern guide-
lines for the diagnosis of PD. It may become mandatory 
to establish the diagnosis of PD very early if a maximum 
disease-modifying or neuroprotective effect of the mod-
ern PD drugs is to be achieved.
 In current clinical practice, clinical criteria for the di-
agnosis of PD will mostly remain to be motor symptoms, 
as discussed above. Additional non-motor symptoms 
which often develop later than motor symptoms will sup-
port a pre-existing diagnosis of PD. A useful tool for ear-
ly diagnosis is the so-called levodopa test, where patients 
receive 200 mg levodopa – this should improve their mo-
tor skills by at least 30%. The clinical signs and the le-
vodopa test will remain the corner-stones of PD diagnosis 
until further techniques emerge. 
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